Observational studyTropical medicine & international health : TM & IH2026
Serum Neurofilament Light Chain Levels in Leprosy Patients: A Cross-Sectional Study.
Observational study in Tropical medicine & international health : TM & IH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLeprosy causes nerve damage which may be clinical or subclinical. Leprosy-associated peripheral neuropathy (LPN) has an unpredictable course despite treatment with multi drug therapy, and results in significant disabilities and stigma. There are no reliable biomarkers to quantify nerve damage in leprosy or predict impending clinical neuropathy.
methodsWe conducted a cross-sectional observational study over 1 year. Leprosy patients with peripheral neuropathy (LPN, n = 30), leprosy patients without detectable peripheral neuropathy (L, n = 20) and healthy controls (HC, n = 20) were included. Patients with other known causes of peripheral neuropathy were excluded. The primary outcome was to estimate serum neurofilament light chain (NfL) levels using the Single Molecular Assay (SiMoA) HD-X analyzer. NfL concentrations were compared across the three groups and correlated with disease spectrum, bacterial load and severity of nerve function impairment (NFI).
resultsThe median NfL level in the LPN group was 12.1 pg/mL (range: -1.68 to 224), in the L group was 17.25 pg/mL (range: 4.43-53.8) and in HCs was 4.85 pg/mL (range: 0.252-23.7). Leprosy patients had significantly higher NfL levels than healthy controls (p = 0.008), with a cut-off value of 7.48 pg/mL using ROC analysis (sensitivity 76%; specificity 25%). NfL levels between the LPN and L groups were comparable (p = 0.56). No significant correlation was found between NfL levels and severity of clinical neuropathy, although a non-significant positive trend with the bacterial index was noted.
conclusionsSerum NfL levels were significantly higher in leprosy patients compared to healthy controls, suggesting prominent axonal damage. NfL may serve as a minimally invasive biomarker of nerve damage in leprosy, but further longitudinal studies are needed to validate its predictive and therapeutic utility in LPN.
trial registrationCTRI/2024/04/081960.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.